HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01377857 |
Recruitment Status
:
Completed
First Posted
: June 21, 2011
Last Update Posted
: May 14, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Behavioral: Monetary Incentive Behavioral: Questionnaire Timing Behavioral: HIV Test Offering | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8572 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies |
Study Start Date : | May 2011 |
Actual Primary Completion Date : | December 2013 |
Actual Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Opt-In
Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
|
Behavioral: HIV Test Offering
HIV Test will be offered as opt-in, opt-out, or active choice.
|
Experimental: Opt-Out
Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
|
Behavioral: HIV Test Offering
HIV Test will be offered as opt-in, opt-out, or active choice.
|
Experimental: Active Choice
In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
|
Behavioral: HIV Test Offering
HIV Test will be offered as opt-in, opt-out, or active choice.
|
Experimental: $1 Incentive
When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
|
Behavioral: Monetary Incentive
$1, $5, or $10 incentive
|
Experimental: $5 Incentive
When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
|
Behavioral: Monetary Incentive
$1, $5, or $10 incentive
|
Experimental: $10 Incentive
When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
|
Behavioral: Monetary Incentive
$1, $5, or $10 incentive
|
Experimental: Early Questionnaire
At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
|
Behavioral: Questionnaire Timing
Timing of the questionnaire--either before or after testing is offered.
|
Experimental: Late Questionnaire
At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
|
Behavioral: Questionnaire Timing
Timing of the questionnaire--either before or after testing is offered.
|
Experimental: FITD Questionnaire
There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: "If you were offered an HIV test as part of your routine health care at no cost, would you get tested?" The two questionnaires will be otherwise identical.
|
Behavioral: Questionnaire Timing
Timing of the questionnaire--either before or after testing is offered.
|
Experimental: Free
When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
|
Behavioral: Monetary Incentive
$1, $5, or $10 incentive
|
- Proportion of patients offered an HIV test who accept [ Time Frame: Monthly ]
- Proportion testing HIV positive of those tested [ Time Frame: Monthly ]
- Proportion testing HIV positive among those offered a test [ Time Frame: Monthly ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 64 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients aged 13 - 64 years who are awake, alert, not intoxicated, and understand the premise of the test will be offered the test and questionnaire according to their treatment group.
Exclusion Criteria:
- Patients who have altered levels of consciousness, are critically ill (e.g., serious trauma), are known to have preexisting HIV diagnosis, or who have been tested for HIV in the past 3 months will be excluded from the study.
- Pregnant patients will be excluded due to alternative guidelines for incorporating opt-out testing during prenatal care.
- Any patients who are in police custody will also be excluded due to their lack of control over study participation decisions and ethical concerns over possible coercion.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01377857
United States, California | |
San Francisco General Hospital | |
San Francisco, California, United States, 94122 |
Principal Investigator: | Beth Kaplan, MD | University of California, San Francisco | |
Principal Investigator: | William H Dow, PhD | University of California, Berkeley |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT01377857 History of Changes |
Other Study ID Numbers: |
10562983 1RC4AG039078-01 ( U.S. NIH Grant/Contract ) |
First Posted: | June 21, 2011 Key Record Dates |
Last Update Posted: | May 14, 2015 |
Last Verified: | May 2015 |